TNSN02036A1 - Derives d'acide 3- heterocyclylpropano-hydroxamique nouveaux, et compositions les contenant. - Google Patents

Derives d'acide 3- heterocyclylpropano-hydroxamique nouveaux, et compositions les contenant.

Info

Publication number
TNSN02036A1
TNSN02036A1 TNTNSN02036A TNSN02036A TNSN02036A1 TN SN02036 A1 TNSN02036 A1 TN SN02036A1 TN TNSN02036 A TNTNSN02036 A TN TNSN02036A TN SN02036 A TNSN02036 A TN SN02036A TN SN02036 A1 TNSN02036 A1 TN SN02036A1
Authority
TN
Tunisia
Prior art keywords
compositions containing
heterocyclylpropano
new
acid derivatives
hydroxamic acid
Prior art date
Application number
TNTNSN02036A
Other languages
English (en)
Inventor
Bailey Simon
Vincent Fish Paul
James Kim
Alistair Whitlock Gavin
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of TNSN02036A1 publication Critical patent/TNSN02036A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'INVENTION CONCERNE DES COMPOSES DE FORMULE (I) : DANS LAQUELLE X ET R REPRESENTENT DES RADICAUX ORGANIQUES, (HET) REPRESENTANT UN GROUPEMENT HETEROCYCLIQUE DIVALENT ET Y REPRESENTE UN NOYAU MONO OU BICYCLIQUE INSATURE. ELLE CONCERNE EGALEMENT DES COMPOSITIONS LES CONTENANT ET UN PROCEDE POUR LEUR PREPARATION. APPLICATION : UTILISATION DE CES COMPOSES ET COMPOSITIONS POUR LE TRAITEMENT DE MALADIES A MEDIATION PAR LA PCP.
TNTNSN02036A 2001-03-30 2002-03-29 Derives d'acide 3- heterocyclylpropano-hydroxamique nouveaux, et compositions les contenant. TNSN02036A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0108102.5A GB0108102D0 (en) 2001-03-30 2001-03-30 Compounds

Publications (1)

Publication Number Publication Date
TNSN02036A1 true TNSN02036A1 (fr) 2005-12-23

Family

ID=9911984

Family Applications (1)

Application Number Title Priority Date Filing Date
TNTNSN02036A TNSN02036A1 (fr) 2001-03-30 2002-03-29 Derives d'acide 3- heterocyclylpropano-hydroxamique nouveaux, et compositions les contenant.

Country Status (16)

Country Link
EP (1) EP1373264B1 (fr)
JP (1) JP2004524365A (fr)
AP (1) AP2002002466A0 (fr)
AT (1) ATE285409T1 (fr)
BR (1) BR0208499A (fr)
CA (1) CA2442481A1 (fr)
DE (1) DE60202358T2 (fr)
ES (1) ES2232740T3 (fr)
GB (1) GB0108102D0 (fr)
GT (1) GT200200062A (fr)
MX (1) MXPA03008944A (fr)
PA (1) PA8542201A1 (fr)
PE (1) PE20021045A1 (fr)
TN (1) TNSN02036A1 (fr)
UY (1) UY27236A1 (fr)
WO (1) WO2002079200A1 (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3632902B1 (fr) 2003-04-11 2021-07-14 PTC Therapeutics, Inc. Composé d'acide benzoïque 1,2,4-oxadiazole et son utilisation pour la suppression non-sens et le traitement de maladies
WO2005058876A1 (fr) * 2003-12-16 2005-06-30 Gpc Biotech Ag Derives de la pyrazine utilises en tant que composes efficaces contre les maladies infectieuses
DE102004003812A1 (de) * 2004-01-25 2005-08-11 Aventis Pharma Deutschland Gmbh Arylsubstituierte Heterozyklen, Verfahren ihrer Herstellung und ihre Verwendung als Arzneimittel
US7319108B2 (en) 2004-01-25 2008-01-15 Sanofi-Aventis Deutschland Gmbh Aryl-substituted heterocycles, process for their preparation and their use as medicaments
EP1742935B1 (fr) 2004-04-13 2010-02-24 Icagen, Inc. Pyrazines polycycliques tenant lieu de modulateurs du canal ionique du potassium
BRPI0608604B8 (pt) 2005-05-10 2021-05-25 Incyte Corp moduladores de 2,3-dioxigenase de indolamina e composição farmacêutica
CA2634198C (fr) 2005-12-20 2014-06-03 Incyte Corporation N-hydroxyamidinoheterocycles en tant que modulateurs d'indoleamine 2,3-dioxygenase
US20080125470A1 (en) 2006-09-19 2008-05-29 Incyte Corporation N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
CL2007002650A1 (es) * 2006-09-19 2008-02-08 Incyte Corp Compuestos derivados de heterociclo n-hidroxiamino; composicion farmaceutica, util para tratar cancer, infecciones virales y desordenes neurodegenerativos entre otras.
DE102007025718A1 (de) 2007-06-01 2008-12-04 Merck Patent Gmbh Pyridazinonderivate
PT2824100T (pt) 2008-07-08 2018-05-10 Incyte Holdings Corp 1,2,5-oxadiazoles como inibidores da indoleamina 2,3-dioxigenase
JP5753104B2 (ja) 2009-03-03 2015-07-22 メルク セローノ ソシエテ アノニム Ｓ１ｐ１レセプターアゴニストとして有用なオキサゾールピリジン誘導体
ES2799582T3 (es) 2013-11-08 2020-12-18 Incyte Holdings Corp Proceso para la síntesis de un inhibidor de indoleamina 2,3-dioxigenasa
EA031654B1 (ru) * 2014-01-10 2019-02-28 Глэксосмитклайн Интеллекчуал Проперти (No.2) Лимитед Гидроксиформамидные производные и их применение
KR102497273B1 (ko) 2014-03-06 2023-02-07 피티씨 테라퓨틱스, 인크. 1,2,4-옥사디아졸 벤조산의 약학 조성물 및 염
BR112018008838A8 (pt) 2015-10-30 2019-02-26 Ptc Therapeutics Inc método para tratar, prevenir, melhorar ou administrar uma doença epiléptica

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9725782D0 (en) * 1997-12-05 1998-02-04 Pfizer Ltd Therapeutic agents
AU3196200A (en) * 1999-03-26 2000-10-16 Shionogi & Co., Ltd. Beta-amino acid derivatives
GB9930570D0 (en) * 1999-12-23 2000-02-16 Pfizer Ltd Therapy

Also Published As

Publication number Publication date
WO2002079200A1 (fr) 2002-10-10
PA8542201A1 (es) 2002-10-28
EP1373264B1 (fr) 2004-12-22
AP2002002466A0 (en) 2002-06-30
ES2232740T3 (es) 2005-06-01
ATE285409T1 (de) 2005-01-15
GT200200062A (es) 2003-11-15
MXPA03008944A (es) 2003-12-08
DE60202358T2 (de) 2005-12-08
UY27236A1 (es) 2002-11-29
JP2004524365A (ja) 2004-08-12
PE20021045A1 (es) 2002-11-19
BR0208499A (pt) 2004-04-20
GB0108102D0 (en) 2001-05-23
DE60202358D1 (en) 2005-01-27
CA2442481A1 (fr) 2002-10-10
EP1373264A1 (fr) 2004-01-02

Similar Documents

Publication Publication Date Title
TNSN02036A1 (fr) Derives d'acide 3- heterocyclylpropano-hydroxamique nouveaux, et compositions les contenant.
TNSN99106A1 (fr) Derives d'isothiazole nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant.
TNSN00104A1 (fr) Derives d'isothiazole nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN00036A1 (fr) Acides oxamiques nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant.
TNSN97145A1 (fr) Derives 6,5-heterobicycliques substitues, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN99073A1 (fr) Pyrazolopyrimidinones nouvelles, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN99169A1 (fr) Derives de 4,4-biarylpiperidine nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN00092A1 (fr) Composes nouveaux antagonistes de npy, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN97192A1 (fr) Derives de pyrimidine bicycliques condenses, procede pour leur preparation et compositions pharmaceutiques les contenant.
TNSN99236A1 (fr) Derives bicycliques substitues nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant.
TNSN00065A1 (fr) Derives nouveaux de pyrimidine inhibiteurs de sorbitol- deshydrogenase, leur procede de preparation et compositions pharmaceutiques les contenant.
TNSN98019A1 (fr) Derives d'acide arylsulfonylaminohydroxamique, procede pour leur preparation et compositions pharmaceutiques les contenant.
MA26697A1 (fr) Composes nouveaux inhibiteurs de gsk-3 et compositions pharmaceutiques les contenant
TNSN01102A1 (fr) Derives de pyrazole nouveaux, procede pour leur preparation et compositions les contenant.
TNSN98150A1 (fr) Derives d'acides aryloxyarylsulfonylaminohydroxamiques ; procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN99031A1 (fr) Composes heterocycliques nouveaux inhibiteurs de romatases, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN99110A1 (fr) Inhibiteurs non peptidiques de l'adhesion cellulaire sous la dependance de vla-4, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN02021A1 (fr) Derives de benzimidazole nouveaux, et compositions les contenant
TNSN98194A1 (fr) Derives nouveaux de 6-o-methylerythromycine a, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN99156A1 (fr) Derives d'acide hydroxypipecolate-hydroxamique nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN99155A1 (fr) 1-aryl-3-arylmethyl-1,8-naphtyridine-4(1h)-ones nouvelles, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN99253A1 (fr) Composes chimiques nouveaux modulateurs de ccr5, et compositions pharmaceutiques les contenant.
TNSN98036A1 (fr) Derives d'acide hexanoique nouveaux
TNSN97148A1 (fr) Derives d'indazole nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN98066A1 (fr) Derives de tetrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.